Headlines about ImmunoGen (NASDAQ:IMGN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ImmunoGen earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.5616123568527 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
Several research firms have recently weighed in on IMGN. ValuEngine downgraded ImmunoGen from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. Canaccord Genuity reaffirmed a “buy” rating and set a $10.00 price objective (up from $8.00) on shares of ImmunoGen in a research note on Wednesday, August 30th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $5.00 price objective on shares of ImmunoGen in a research note on Monday, September 25th. Jefferies Group restated a “buy” rating and issued a $9.00 price target on shares of ImmunoGen in a report on Thursday, October 12th. Finally, Cowen reissued a “hold” rating on shares of ImmunoGen in a research note on Tuesday, August 29th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $7.83.
ImmunoGen (IMGN) opened at $6.18 on Tuesday. The company has a quick ratio of 2.78, a current ratio of 2.81 and a debt-to-equity ratio of -0.03. ImmunoGen has a 52 week low of $1.53 and a 52 week high of $8.84.
ImmunoGen (NASDAQ:IMGN) last issued its earnings results on Friday, November 3rd. The biotechnology company reported ($0.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.42). The business had revenue of $8.50 million during the quarter, compared to the consensus estimate of $26.09 million. During the same period in the prior year, the firm posted ($0.51) EPS. The firm’s revenue for the quarter was up 10.4% compared to the same quarter last year. equities analysts predict that ImmunoGen will post -0.98 EPS for the current fiscal year.
In related news, VP Craig Barrows sold 37,050 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $6.81, for a total transaction of $252,310.50. Following the sale, the vice president now owns 51,100 shares of the company’s stock, valued at $347,991. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 6.51% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “ImmunoGen (IMGN) Given Daily News Sentiment Score of 0.15” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/12/12/immunogen-imgn-receiving-somewhat-favorable-press-coverage-accern-reports.html.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.